President, CEO and Chairman, Vanda Pharmaceuticals
Appears in 2 stories
Leading the FDA discussion and sNDA submission for DSWPD
Vanda Pharmaceuticals said a late-stage trial of HETLIOZ (tasimelteon) shifted the timing of sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder (DSWPD). The result was statistically significant (p=0.022), and 60% of treated patients advanced their sleep by at least 30 minutes, versus 15% on placebo.
Updated Sep 30
Leading Vanda through dual drug launches in 2026
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
